Skip to main
SGRY
SGRY logo

Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners (SGRY) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 38%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Surgery Partners Inc. is experiencing favorable payor mix dynamics, with private insurance revenue share increasing by 100 basis points to 53.5%, while government payor mix decreased, indicating a healthier revenue structure. The company reported an impressive organic revenue growth of 8.0% year-over-year in 2024, driven by a 5.1% growth in same-facility day-adjusted case volume and a 4.0% increase in revenue per case, which are expected to continue benefiting from strategic investments in higher acuity specialties. Additionally, adjusted EBITDA margins improved, with a rise from 16.0% to 16.3%, and 2025 guidance anticipates further margin expansion to 16.4%-16.8%, supported by effective revenue-cycle management and operational efficiencies.

Bears say

Surgery Partners Inc. has experienced a fourth-quarter adjusted EBITDA margin of 18.9%, which is below both the market expectations of 19.8% and the 19.4% recorded in the same quarter of the previous year, despite a slight increase in revenue. The company’s stock has seen a significant decline of 31% since the last earnings report, attributed to disappointed investor sentiment stemming from higher transaction-related costs and negative revisions to free cash flow and earnings per share. Additionally, upcoming healthcare policy uncertainties and projected revenue and EBITDA headwinds for 2025 further contribute to a negative outlook for the company’s financial performance.

Surgery Partners (SGRY) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 38% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surgery Partners (SGRY) Forecast

Analysts have given Surgery Partners (SGRY) a Buy based on their latest research and market trends.

According to 16 analysts, Surgery Partners (SGRY) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surgery Partners (SGRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.